Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02978716
Title Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.

triple-receptor negative breast cancer


Carboplatin + Gemcitabine

Carboplatin + Gemcitabine + Trilaciclib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.